The new anti-smoking drug varenicline was first licensed for use in the UK on 5th December 2006. An early Cochrane Review' of its effectiveness shows that it can give a three-fold increase in the odds of a person quitting smoking. Varenicline is the first new anti-smoking drug in the last ten years, and only the third, after NRT and bupropion, to be licensed in the USA for smoking cessation.
People become addicted to smoking tobacco partly because nicotine in the smoke stimulates receptors in the nervous system that cause a release of the feel-good hormone dopamine. Varenicline partially stimulates these nicotine receptors and enables a low-level release of dopamine, which reduces withdrawal symptoms. It also partially blocks nicotine from being absorbed by the receptors, making continued smoking less satisfying. This reduces a person’s need to smoke, and may help them to quit completely.
This conclusion was drawn by a group of Cochrane researchers after they studied data from six trials that compared the effects of giving people either varenicline or a placebo. Together the trials involved 2451 people on varenicline and 2473 people on placebos.
Pooling the data showed that people taking varenicline increased their odds of quitting approximately three-fold for 12 months or longer compared with those on placebo drugs .
Data from some of the trials also showed that people given varenicline increased their odds of quitting more than 1½-fold compared with those given bupropion, an antidepressant drug that roughly doubles a person’s chance of stopping smoking (see: next press release.)
“What we need now are some trials that make direct comparisons between varenicline and nicotine replacement therapy” says Lead Review Author Kate Cahill, who works in the Department of Primary Health Care at Oxford University.
Julia Lampam | alfa
UC San Diego researchers develop sensors to detect and measure cancer's ability to spread
06.12.2018 | University of California - San Diego
New cancer immunotherapy approach turns immune cells into tiny anti-tumor drug factories
05.12.2018 | University of California - San Diego
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals
Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.
Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.
Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...
Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.
The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.
06.12.2018 | Event News
03.12.2018 | Event News
28.11.2018 | Event News
07.12.2018 | Life Sciences
07.12.2018 | Materials Sciences
07.12.2018 | Physics and Astronomy